Sonic Healthcare Ltd (ASX: SHL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sonic Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sonic Healthcare Ltd (ASX: SHL)
Latest News
Dividend Investing
Retail and health: Analysts say these ASX 300 dividend shares are buys
Best Shares
Top ASX shares to buy in August 2023
Dividend Investing
How I’d start earning passive income from ASX shares to supplement my wages
Dividend Investing
3 things to consider when looking for reliable ASX dividend payers
Share Market News
3 ASX shares using AI to help supercharge profits
Healthcare Shares
Should I buy Sonic Healthcare shares at $35?
How to invest
3 ASX investing trends to consider right now
Dividend Investing
3 ASX dividend shares I think are the safest buys right now
Dividend Investing
Reinvestment royalty: 2 ASX 200 shares masterfully growing their dividends
Dividend Investing
Trying to find ASX shares with consistent dividends? Look for these 3 traits
Dividend Investing
Brokers say these ASX dividend shares are buys
Share Gainers
Why BCI Minerals, Collins Foods, Dexus, and Sonic shares are rising today
Frequently Asked Questions
-
Sonic Healthcare historically makes two partially or fully franked dividend payments to shareholders each year.
-
Sonic Healthcare generally pays its shareholder dividends in March and September.
-
Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.
-
Sonic Healthcare Ltd listed on the ASX on 30 April 1987.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
07 Mar 2023 | $0.4200 | 100.00% | Interim | 22 Mar 2023 |
06 Sep 2022 | $0.6000 | 100.00% | Final | 21 Sep 2022 |
08 Mar 2022 | $0.4000 | 100.00% | Interim | 23 Mar 2022 |
07 Sep 2021 | $0.5500 | 65.00% | Final | 22 Sep 2021 |
09 Mar 2021 | $0.3600 | 30.00% | Interim | 24 Mar 2021 |
07 Sep 2020 | $0.5100 | 30.00% | Final | 22 Sep 2020 |
10 Mar 2020 | $0.3400 | 30.00% | Interim | 25 Mar 2020 |
10 Sep 2019 | $0.5100 | 30.00% | Final | 25 Sep 2019 |
08 Mar 2019 | $0.3300 | 20.00% | Interim | 26 Mar 2019 |
12 Sep 2018 | $0.4900 | 30.00% | Final | 27 Sep 2018 |
06 Mar 2018 | $0.3200 | 20.00% | Interim | 10 Apr 2018 |
08 Sep 2017 | $0.0000 | 0.00% | Final | 11 Oct 2017 |
07 Mar 2017 | $0.3100 | 20.00% | Interim | 11 Apr 2017 |
08 Sep 2016 | $0.4400 | 30.00% | Final | 27 Sep 2016 |
03 Mar 2016 | $0.3000 | 30.00% | Interim | 06 Apr 2016 |
05 Sep 2014 | $0.4000 | 55.00% | Final | 23 Sep 2014 |
03 Sep 2012 | $0.2923 | 53.88% | Final | 09 Oct 2012 |
04 Mar 2011 | $0.1881 | 35.62% | Interim | 24 Mar 2011 |
08 Sep 2010 | $0.2818 | 43.47% | Final | 28 Sep 2010 |
03 Mar 2010 | $0.1932 | 43.48% | Interim | 25 Mar 2010 |
08 Sep 2009 | $0.2818 | 43.47% | Final | 28 Sep 2009 |
05 Mar 2009 | $0.1936 | 68.18% | Interim | 26 Mar 2009 |
08 Sep 2008 | $0.3200 | 100.00% | Final | 09 Oct 2008 |
28 Feb 2006 | $0.1500 | 100.00% | Interim | 20 Mar 2006 |
31 Aug 2005 | $0.2300 | 100.00% | Final | 19 Sep 2005 |
26 Feb 2004 | $0.1000 | 100.00% | Interim | 17 Mar 2004 |
SHL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Sonic Healthcare Ltd
Sonic Healthcare Limited (ASX: SHL) is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland. It is the second-largest provider in Belgium and New Zealand and the third-largest in the United States.
While pathology contributes the vast majority of the company's revenue, Sonic Healthcare is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.
The company typically earns the majority of its revenue from its European pathology segment, followed by its Australia-New Zealand pathology operations.
SHL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 Aug 2023 | $34.21 | $-0.04 | -0.12% | 614,999 | $34.19 | $34.26 | $34.10 |
08 Aug 2023 | $34.25 | $0.20 | 0.59% | 896,178 | $34.06 | $34.34 | $34.01 |
07 Aug 2023 | $34.05 | $-0.05 | -0.15% | 606,609 | $33.98 | $34.32 | $33.93 |
04 Aug 2023 | $34.10 | $-0.36 | -1.04% | 1,150,992 | $34.18 | $34.37 | $33.78 |
03 Aug 2023 | $34.46 | $-0.07 | -0.20% | 793,454 | $34.53 | $34.88 | $34.18 |
02 Aug 2023 | $34.53 | $-0.59 | -1.68% | 879,265 | $35.12 | $35.12 | $34.48 |
01 Aug 2023 | $35.12 | $-0.03 | -0.09% | 549,250 | $34.73 | $35.24 | $34.64 |
31 Jul 2023 | $35.15 | $0.23 | 0.66% | 582,551 | $35.15 | $35.21 | $34.91 |
28 Jul 2023 | $34.92 | $-0.58 | -1.63% | 684,580 | $35.35 | $35.35 | $34.80 |
27 Jul 2023 | $35.50 | $0.34 | 0.97% | 1,224,521 | $34.90 | $35.54 | $34.90 |
26 Jul 2023 | $35.16 | $0.12 | 0.34% | 665,671 | $35.34 | $35.46 | $35.07 |
25 Jul 2023 | $35.04 | $-0.46 | -1.30% | 1,103,693 | $35.39 | $35.45 | $34.77 |
24 Jul 2023 | $35.50 | $0.16 | 0.45% | 797,504 | $35.41 | $35.53 | $35.16 |
21 Jul 2023 | $35.34 | $0.27 | 0.77% | 981,235 | $35.35 | $35.67 | $35.08 |
20 Jul 2023 | $35.07 | $-0.24 | -0.68% | 914,720 | $35.52 | $35.73 | $35.07 |
19 Jul 2023 | $35.31 | $-0.28 | -0.79% | 1,025,251 | $35.60 | $35.67 | $35.10 |
18 Jul 2023 | $35.59 | $-0.44 | -1.22% | 1,066,422 | $35.92 | $36.06 | $35.33 |
17 Jul 2023 | $36.03 | $0.32 | 0.90% | 886,900 | $36.15 | $36.33 | $36.02 |
14 Jul 2023 | $35.71 | $0.53 | 1.51% | 934,432 | $35.36 | $35.91 | $35.33 |
13 Jul 2023 | $35.18 | $0.54 | 1.56% | 937,567 | $34.95 | $35.39 | $34.94 |
12 Jul 2023 | $34.64 | $-0.19 | -0.55% | 722,100 | $34.95 | $34.98 | $34.61 |
11 Jul 2023 | $34.83 | $0.46 | 1.34% | 619,668 | $34.65 | $34.85 | $34.61 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 Mar 2023 | Christopher Wilks | Exercise | 37 | $1,261,324 |
Conversion of securities. 57,896 Rights
|
08 Mar 2023 | Christopher Wilks | Issued | 37 | $1,261,324 |
Conversion of securities.
|
08 Mar 2023 | Christopher Wilks | Transfer | 19 | $669,260 |
As advised by the company. 19,966 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
|
08 Mar 2023 | Christopher Wilks | Transfer | 19 | $669,260 |
As advised by the company. 19,966 shares were withdrawn from SHEST and legal title transferred to Mr Wilks.
|
08 Mar 2023 | Colin Goldschmidt | Transfer | 44 | $1,506,422 |
As advised by the company. 44,941 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
|
08 Mar 2023 | Colin Goldschmidt | Issued | 78 | $2,642,616 |
Conversion of securities.
|
08 Mar 2023 | Colin Goldschmidt | Exercise | 78 | $2,642,616 |
Conversion of securities. 1,44,341 performance rights
|
08 Mar 2023 | Colin Goldschmidt | Transfer | 44 | $1,506,422 |
As advised by the company. 44,941 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt.
|
17 Nov 2022 | Colin Goldschmidt | Issued | 265 | $8,687,443 |
Issue of options.
|
17 Nov 2022 | Colin Goldschmidt | Issued | 46 | $1,527,387 |
Issue of securities. 2,23,178 Performance rights
|
17 Nov 2022 | Christopher Wilks | Issued | 19 | $640,952 |
Issue of securities. 95,525 performance rights
|
17 Nov 2022 | Christopher Wilks | Issued | 111 | $3,645,612 |
Issue of options.
|
07 Oct 2022 | Katharine Giles | Buy | 1 | $31,720 |
On-market trade.
|
30 Sep 2022 | Christine Bennett | Buy | 1 | $30,500 |
On-market trade.
|
27 Sep 2022 | Christopher Wilks | Transfer | 2 | $80,335 |
As advised by the company. legally transferred
|
27 Sep 2022 | Christopher Wilks | Issued | 21 | $660,665 |
Issue of securities. 75,906 Rights
|
27 Sep 2022 | Christopher Wilks | Transfer | 2 | $80,335 |
As advised by the company. legally transferred
|
27 Sep 2022 | Christopher Wilks | Sell | 200 | $6,008,820 |
On-market trade.
|
26 Sep 2022 | Colin Goldschmidt | Transfer | 6 | $181,766 |
As advised by the company. legally transferred
|
26 Sep 2022 | Colin Goldschmidt | Issued | 41 | $1,247,806 |
Issue of securities. 1,76,426 RIGHTS
|
26 Sep 2022 | Colin Goldschmidt | Transfer | 6 | $181,766 |
As advised by the company. legally transferred
|
26 Sep 2022 | Colin Goldschmidt | Sell | 331 | $9,936,351 |
On-market trade.
|
23 Sep 2022 | Kathryn (Kate) Spargo | Buy | 2 | $59,437 |
On-market trade.
|
23 Sep 2022 | Mark Compton | Buy | 2 | $59,459 |
On-market trade.
|
21 Sep 2022 | Suzanne Crowe | Buy | 2 | $77,170 |
On-market trade.
|
07 Sep 2022 | Colin Goldschmidt | Transfer | 331 | $10,689,204 |
As advised by the company. shares were withdrawn
from SHEST and legal title transferred to Dr Goldschmidt. |
07 Sep 2022 | Colin Goldschmidt | Transfer | 331 | $10,689,204 |
As advised by the company. shares were withdrawn
from SHEST and legal title transferred to Dr Goldschmidt. |
07 Sep 2022 | Christopher Wilks | Transfer | 147 | $4,748,790 |
As advised by the company. shares were withdrawn from
SHEST and legal title transferred to Mr Wilks. |
07 Sep 2022 | Christopher Wilks | Transfer | 147 | $4,748,790 |
As advised by the company. Shares were withdrawn from
SHEST and legal title transferred to Mr Wilks. |
06 Sep 2022 | Christopher Wilks | Exercise | 147 | $3,187,463 |
Exercise of options.
|
06 Sep 2022 | Christopher Wilks | Issued | 147 | $3,187,463 |
Exercise of options.
|
06 Sep 2022 | Colin Goldschmidt | Exercise | 331 | $7,174,763 |
Exercise of options.
|
06 Sep 2022 | Colin Goldschmidt | Issued | 331 | $7,174,763 |
Exercise of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Christopher David Wilks | Chief Financial OfficerFinance Director | Dec 1989 |
Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. He has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a Nonexecutive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996.
|
Dr Colin Stephen Goldschmidt | Chief Executive OfficerManaging Director | Jan 1993 |
Dr Goldschmidt is the CEO and Managing Director of Sonic Healthcare. He is a medical doctor who then undertook specialist pathology training in Sydney, before gaining his qualification as a specialist pathologist in 1986. Dr Goldschmidt became CEO of Sonic in 1993 and has led Sonic's global expansion by committing the Company to a model of Medical Leadership, which incorporates operational and cultural attributes. He is a member of Sonic's Risk Management Committee and holds memberships with range of industry, medical and laboratory associations.
|
Mr Mark Raymond Compton | Non-Executive DirectorNon-Executive Chairman | Oct 2014 |
Prof Compton has senior executive experience in healthcare services. His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. He was also Chief Executive Officer and Managing Director of the formerly ASX-listed companies SciGen Limited and Alpha Healthcare Limited. Prof. Compton has also held a number of non-executive director roles, including for formerly ASX-listed Independent Practitioner Network Limited, Chairman of the Woolcock Institute of Medical Research, nonexecutive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 45 years). In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017.
|
Mr Neville Mitchell | Non-Executive Director | Sep 2017 |
Mr Mitchell is a non-executive Director of QBiotics (from November 2017), an unlisted public company, and a Member of the Australian Board of Taxation. He has also previously performed roles with a number of industry and government committees, including Chairman of the Group of 100 (Australia's peak body for senior finance executives), and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission (ASIC). He is a member of the Risk Management committee.
|
Mr Louis (Lou) James Panaccio | Non-Executive Director | Jun 2005 |
Mr Panaccio is a Chartered Accountant with executive management experience in business and healthcare services. He is also a non-executive Director of Unison Housing Limited, Invictus Biopharma Limited and NeuralDx Limited. Mr Panaccio was the Chief Executive Officer and executive Director of Melbourne Pathology (acquired by Sonic in 1999) for 10 years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the executive Chairman of Health Networks Australia until 2017. He is a member of the Risk Management committee.
|
Professor Suzanne Crowe | Non-Executive Director | Apr 2020 |
Professor Crowe has more than 30 years of experience as a clinical researcher. She was an part of Burnet's development as a HIV research organisation and held many leadership roles including Program Director, Healthy Ageing and Head of the Centre for Virology. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She was appointed as a Member of the Order of Australia (AM) in 2011 in recognition of her services to medical research in HIV/AIDS medicine and infectious diseases as an academic, clinician and researcher, and to professional associations.
|
Professor Christine Constance Bennett | Non-Executive Director | Sep 2022 |
Prof Bennett has over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Her roles have involved providing clinical care, strategic planning, and senior operational management. She has an active commitment to and involvement in medical professional issues, social policy and medical research. She is an experienced non-executive director in publicly listed, private and social enterprises. She is currently a non-executive director of ASX-listed Regis Healthcare (since March 2018), and an outgoing non-executive director of Telstra Health Pty Ltd. In December 2021, Professor Bennett retired from The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships (in 2020 and 2021) and Dean, School of Medicine, Sydney for over ten years. Her professional experience has included being Group Executive and Chief Medical Officer for MBF and the Bupa Health and Care services, CEO and later Chair of Research Australia, Managing Director of Total Health Enterprise Ltd, Partner in Health and Life Sciences for KPMG Australia, CEO of Westmead Hospital and Community Health Services, General Manager for the Royal Hospital for Women and Head of Planning in NSW Health.
|
Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Jul 2010 |
Ms Spargo has gained business experience as both a legal advisor, having worked in private practice and government, and as a director. Ms Spargo has been a director of both listed and unlisted companies over the last 20 years and her current directorships include the ASX-listed companies CIMIC Group Limited (from September 2017), Adairs Limited (from May 2015) and Sigma Healthcare Limited (from December 2015). She is also a non-executive Director of CoInvest Limited, the Future Fuels Cooperative Research Centre, and Geelong Football Club Limited. Ms Spargo was previously a non-executive Director of Fletcher Building Limited (March 2012 to September 2017), UGL Limited (October 2010 to January 2017) and Xenith IP Group Limited (from April 2017 until 15 August 2019).
|
Dr Katharine Giles | Non-Executive Director | Sep 2022 |
Dr Giles after initially practicing as a medical doctor, Dr Giles moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which specialises in biomedical innovation. Dr Giles is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specialising in seed-to-early-stage technology investment. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private healthcare-related technology companies. She is a member of the Curtin University Commercialisation Advisory Board.
|
Mr Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
|
Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 176,297,372 | 37.33% |
J P Morgan Nominees Australia Pty Limited | 59,466,504 | 12.59% |
Citicorp Nominees Pty Limited | 35,284,909 | 7.47% |
Jardvan Pty Ltd | 15,109,474 | 3.20% |
BNP Paribas Noms Pty Ltd <Drp> | 14,793,282 | 3.13% |
National Nominees Limited | 9,159,727 | 1.94% |
Argo Investments Limited | 3,726,053 | 0.79% |
Australian Foundation Investment Company Limited | 3,159,672 | 0.67% |
Netwealth Investments Limited <Wrap Services A/C> | 2,870,276 | 0.61% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 2,650,108 | 0.56% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 2,517,706 | 0.53% |
Blaise Mentha | 2,000,000 | 0.42% |
Polly Pty Ltd <A/C Patterson Family> | 1,817,416 | 0.38% |
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 1,810,333 | 0.38% |
Bnp Paribas Nominees Pty Ltd Acf Clearstream | 1,645,650 | 0.35% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 1,635,579 | 0.35% |
Australian Executor Trustees Limited <IPS IOOF Employer Super A/C> | 1,615,472 | 0.34% |
Quintal Pty Ltd <Harken Family A/C> | 1,587,908 | 0.34% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 1,359,807 | 0.29% |
Custodial Services Limited <Beneficiaries Holding A/C> | 1,295,861 | 0.27% |